Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4A | O75164 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982951 | 0.95 | KDM4A (0.60) | KMT2ATDP1NPC1CASP3RAB9A | |
| SCHEMBL6338596 | 0.90 | KMT2A (0.77) | KMT2ATDP1NPC1CASP3RAB9A | |
| SCHEMBL11982908 | 0.90 | TMEM97 (0.67) | KMT2ANPC1RAB9ASIGMAR1TMEM97 | |
| Hydrochloric Acid SCHEMBL5181661 | 0.89 | KMT2A (0.74) | KMT2ATDP1NPC1CASP3RAB9A | |
| SCHEMBL11126800 | 0.87 | KMT2A (0.77) | KMT2ATDP1NPC1CASP3RAB9A | |
| Hydrochloric Acid SCHEMBL7449337 | 0.86 | TMEM97 (0.62) | KMT2ANPC1RAB9ASIGMAR1TMEM97 | |
| Hydrochloric Acid SCHEMBL11113894 | 0.86 | KMT2A (0.75) | KMT2ATDP1NPC1CASP3RAB9A | |
| SCHEMBL2676817 | 0.85 | KDM4A (0.67) | NPC1RAB9ASMN1; SMN2SIGMAR1TMEM97 | |
| SCHEMBL8547157 | 0.83 | SIGMAR1 (0.58) | NPC1RAB9ASMN1; SMN2SIGMAR1TMEM97 | |
| Hydrochloric Acid SCHEMBL8891865 | 0.83 | KDM4A (0.68) | SMN1; SMN2SIGMAR1TMEM97L3MBTL1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912649-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-10 | — | — | EP | disclosed |
| CN-101277698-B | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV | 2011-06-22 | — | — | CN | disclosed |
| CN-1910177-B | Substituted quinolines and their use as mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV | 2010-05-05 | — | — | CN | disclosed |
| CN-101277698-A | Quinoline derivatives as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| US-20080227775-A1 | Quinoline Derivatives as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
| EP-1912649-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1711492-B1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-16 | — | — | EP | disclosed |
| US-7338949-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-04 | — | — | US | disclosed |
| WO-2007095756-A1 | NOVEL CENTRAL-NERVOUS SYSTEM ACTING COMPOUNDS AND METHODS FOR THE TREATMENT OF CNS DISORDERS | CLERA INC. (CA) | 2007-08-30 | — | — | WO | disclosed |
| US-20070082895-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-12 | — | — | US | disclosed |
| WO-2007014934-A2 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| CN-1910177-A | Substituted quinolines and their use as mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227775-A1 | Quinoline Derivatives as Antibacterial Agents | NQO2, HRH1, HRH2 | KMT2A 3311/4885TDP1 3482/4885NPC1 1309/4885 |
| US-20070082895-A1 | Novel mycobacterial inhibitors | HRH4, NAT1, CBR3 | KMT2A 3491/4885TDP1 3302/4885NPC1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.